Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., Lancet Rheumatology, doi:10.1016/S2665-9913(20)30305-2 (Peer Reviewed)
Long-term hydroxych loroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Retrospective patients with rheumatologic conditions showing zero mortality with HC
Q, odds ratio OR 0.13, p
=0.10. 0 of 10,703 COVID-19 deaths for HC
Q patients versus 7 of 21,406 for control patients.
COVID-19 cases OR 0.79, p
=0.27. There are several significant differences in the propensity matched patients that could affect results, e.g., 20.9% SLE versus 24.7%.
death, ↓86.7%, p=0.10
COVID-19 case, ↓20.9%, p=0.27
(odds ratio converted to relative risk)
Please send us corrections, updates, or comments.